To: (10)(2e) [(10)(2e) @ecdc.europa.eu] Cc: (10)(2e) [(10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @erasmusmc.nl] From: (10)(2e) [(10)(2e) @erasmusmc.nl] Sent: Fri 7/17/2020 7:14:18 AM
Subject: RE: Euro Surveillance test performance paper - Final review round, due by Fri 17 July Received: Fri 7/17/2020 7:14:31 AM Performance paper 10020 docx
Please find attached the manuscript. Only a few changes have been made. Kind regards,
Van: (10)(2e) [(10)(2e) @rivm.nl] Verzonden: woensdag 15 juli 2020 14:33
Aan: (10)(2e) CC: (10)(2e) ; (10)(2e) Onderwerp: Euro Surveillance test performance paper - Final review round, due by Fri 17 July Urgentie: Hoog
Beste allen,
Hieronder de finale ronde van het reviewen van het paper van de ECDC. Vanwege de strakke deadline: <u>as vrijdag</u> 17.00 uur willen wij jullie vragen om zelf direct naar (10)(2e) van ECDC te reageren via (10)(2e) @ecdc.europa.eu. Instructies zijn te vinden in de mail hieronder.
Als jullie weten van directe collega's die op vakantie zijn en co-auteur zijn, zouden jullie dan daarmee contact op willen nemen of antwoorden namens hun?
Voor de gerapporteerde Nederlandse data is uitgegaan van de ELISA rapportage, versie 2 juni; en de POCT rapportage, versie 26 mei. De geaggregeerde data uit NL is allemaal in de vorige review ronde door ons gecheckt en indien nodig gecorrigeerd.
Vriendelijke groet, (10)(2e) en (10)(2e)
From: (10)(2e) < (10)(2e) @ecdc.europa.eu> Sent: woensdag 15 juli 2020 10:01 Subject: Euro Surveillance test performance paper - Final review round, due by Fri 17 July

Dear co-authors,

After incorporating your comments on the second review round early July, the paper is now ready for its third and final review round by Friday 17 July EOB. Our apologies for the short notice, but we want to avoid issues with people going on holiday and in this third round no major issues are expected anymore.

The following main changes have been done:

- The author list has been finalised and all remaining authors have contributed and verified their data.
- All 117 papers from the systematic review have now been assessed and their data included. Substantially more detail was added on how papers were selected. A verification round performed by ECDC on this assessment is in progress and will be finalised in parallel with this review round. This may result in some changes but unlikely in any conclusions.
- The total number of index test results (contributed by you/from public sources) is currently 39439 (13919/25520) for reference test positive samples (sensitivity panel), and 45804 (14934/30870) for reference test negative samples (specificity panel). With the current exclusions for sensitivity and specificity panels for the public sources, pending verification and before further exclusion based on <=10 dpo for Ab tests, this drops to around 83% and 90% of the total.</p>
- Supplementary tables 2 and 3, i.e. the study list and all performance results are included. These contain the unpublished data from all co-authors and may not be shared with other people.
- References were added.

Attached you will find the paper to review, with all non-contentious tracked changes accepted and corresponding (green) comments removed. Only tracked changes and (yellow) comments that are likely to require further review are included. As before, a version with all tracked changes and comments is attached as well for reference.

You should do the following:

- Review the paper a final time, with particular emphasis on yellow comments and tracked changes. All changes should be tracked.
- Add your consent for submitting the paper preferably now already, in the last column of the author table at the beginning of the document, to avoid delays due to holidays. This can be done after review round 3 as well in particular if you think important points need to be addressed first, but please let us know if you will be unavailable in the near future. If one of your direct colleagues is on leave at present and not back before 20 July, please try to contact them if possible for this consent or provide it on their behalf if you think this is ok.
- If not done yet, add your <u>CRediT</u> (Contributor Roles Taxonomy) statement in the author table at the beginning. A default (investigation, data curation, writing-review) has been put in place for now and will be considered final unless changed.
 Some tracked changes were also made to existing statements to ensure consistency across authors and using the CRediT terminology.
- If not done yet, add any funding and declaration of interest.
- Add any references you think are appropriate, at least one still needs to be added.
- Verify at least one aggregated sensitivity and specificity result from supplementary Table S3 for correctness. Choose one
 for which at least two studies were used. If you find an issue, please reply to me asap. The supplementary tables are inside
 an Excel file embedded into the Word document, and attached as well.


After this review round, comments will be incorporated as before and the paper will be sent for internal clearance at ECDC as per our procedures. We will keep you up to date on the progress with that. In the meantime, please do not hesitate to contact me if there are immediate issues.

Kind regards,

(10)(2e)







Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01

.



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten. www.rivm.ni De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages. www.rivm.nl/en Committed to health and sustainability
Deze e-mail is veilig verstuurd en is veilig bij u als ontvanger in uw gebruikelijke mailbox of in een beveiligde omgeving (KPN Zorgmessenger) afgeleverd. Met het beveiligd versturen van e-mails voldoet Star-shl aan wettelijke regelgeving.